These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 8533995)

  • 1. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.
    Ann Intern Med; 1996 Jan; 124(2):204-11. PubMed ID: 8533995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Wang Y; Parker CE; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD000544. PubMed ID: 27158764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
    Sninsky CA; Cort DH; Shanahan F; Powers BJ; Sessions JT; Pruitt RE; Jacobs WH; Lo SK; Targan SR; Cerda JJ
    Ann Intern Med; 1991 Sep; 115(5):350-5. PubMed ID: 1863024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
    Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.
    Ardizzone S; Petrillo M; Molteni P; Desideri S; Bianchi Porro G
    J Clin Gastroenterol; 1995 Dec; 21(4):287-9. PubMed ID: 8583101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
    Miner P; Hanauer S; Robinson M; Schwartz J; Arora S
    Dig Dis Sci; 1995 Feb; 40(2):296-304. PubMed ID: 7851193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
    Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
    Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L; Cohen H; Dooley C; Rubin P; Orchard J
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
    Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
    Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Sutherland L; Macdonald JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD000544. PubMed ID: 16625537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
    Hawkey CJ; Dube LM; Rountree LV; Linnen PJ; Lancaster JF
    Gastroenterology; 1997 Mar; 112(3):718-24. PubMed ID: 9041232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.